Radiosensitization by BRAF inhibitors.

Area of Science:

• Oncology
• Dermatology
• Medical Radiation

Background:

• Recent reports indicate increased skin toxicity with combined BRAF inhibitor and radiation therapy.
• Melanoma treatment often involves targeted therapies and radiation.

Purpose of the Study:

• To evaluate the safety and efficacy of combined BRAF inhibitor and radiation therapy in melanoma patients.
• To assess the incidence and severity of skin toxicity during this combination treatment.

Main Methods:

• Seven patients with unresectable stage III or IV melanoma received concomitant BRAF inhibitor and radiation therapy.
• Skin toxicity was graded using the Common Terminology Criteria for Adverse Events (CTCAE).

Main Results:

• All patients achieved a good local response.
• Two patients on vemurafenib experienced severe radiation dermatitis (grade 3/4), leading to treatment interruption.
• Mild to moderate dermatitis (grade 1-2) was observed in other patients.
• Recall dermatitis occurred in one patient post-radiation.

Conclusions:

• BRAF inhibitor-induced radiosensitization causing severe skin toxicity is not common and generally treatable.
• Combination therapy remains a valuable option for aggressive melanoma, despite a manageable increase in skin toxicity risk.
• Sequential treatment did not appear to prevent skin toxicity.